Erudio Healtherudio.com
Drug
Selpercatinib trials: what clinicians said in public
No HCP commentary report on a trial studying selpercatinib yet. Erudio has found public clinician commentary on 6 clinical trials studying selpercatinib, including LIBRETTO-432, LIBRETTO-531, ORCHARD and ROME. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| LIBRETTO-432 NCT04819100 · Eli Lilly and Company DeepView → | stage IB-IIIA RET fusion-positive NSCLC | Phase 3 | Deep | View | |||
| ROME NCT04591431 · Fondazione per la Medicina Personalizzata DeepView → | advanced solid tumors | Phase 2 | Deep | View | |||
| LIBRETTO-531 NCT04211337 · Loxo Oncology, Inc. DeepView → | kinase inhibitor-naïve advanced RET-mutant medullary thyroid cancer | Phase 3 | Deep | View | |||
| ORCHARD NCT03944772 · AstraZeneca StandardView → | EGFR-mutated advanced NSCLC after first-line osimertinib | Phase 2 | Standard | View | |||
| LIBRETTO-431 NCT04194944 · Eli Lilly and Company FocusedView → | first-line RET fusion-positive advanced non-small cell lung cancer | Phase 3 | Focused | View | |||
| LIBRETTO-121 NCT03899792 · Eli Lilly and Company FocusedView → | pediatric advanced RET-altered solid or primary CNS tumors | Phase 1/Phase 2 | Focused | View | |||